| scholarly article | Q13442814 |
| P50 | author | Maciej Pastuszczak | Q114219964 |
| Magdalena M. Pirowska | Q124607471 | ||
| Joanna Sułowicz | Q124607486 | ||
| Aleksander Obtułowicz | Q124607522 | ||
| Anna Wojas-Pelc | Q37329016 | ||
| Sylwia Lipko-Godlewska | Q37329450 | ||
| P2093 | author name string | Katarzyna Podolec | |
| Paweł Brzewski | |||
| P2860 | cites work | Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof | Q21246039 |
| Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders | Q38970666 | ||
| Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis | Q41932479 | ||
| Psoriasis patients show signs of insulin resistance | Q46966587 | ||
| Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. | Q51498390 | ||
| Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study | Q85888806 | ||
| Pathogenic T helper type 17 cells contribute to type 1 diabetes independently of interleukin-22 | Q86547079 | ||
| Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus | Q88138483 | ||
| Inflammation, stress, and diabetes | Q24523336 | ||
| Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity | Q24630655 | ||
| Global epidemiology of psoriasis: a systematic review of incidence and prevalence | Q26991871 | ||
| Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data | Q31005025 | ||
| Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction | Q33642021 | ||
| Serum IL-17, IL-23, and TGF-β levels in type 1 and type 2 diabetic patients and age-matched healthy controls | Q33786938 | ||
| Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis | Q34364602 | ||
| Psoriasis and comorbidities: links and risks | Q34418506 | ||
| Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity | Q34945351 | ||
| Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications | Q35045850 | ||
| Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences | Q35115207 | ||
| The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. | Q35135831 | ||
| Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease | Q35377706 | ||
| Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom | Q35753936 | ||
| Adipose tissue, adipokines, and inflammation | Q36114223 | ||
| Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis | Q36500064 | ||
| Psoriasis: genetic associations and immune system changes. | Q36648696 | ||
| Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies | Q36824796 | ||
| Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis | Q36914874 | ||
| Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions | Q37743164 | ||
| The association between psoriasis and dyslipidaemia: a systematic review | Q38056160 | ||
| From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies | Q38159088 | ||
| Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors | Q38166661 | ||
| Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes | Q38221768 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dermatology | Q171171 |
| metabolic syndrome | Q657193 | ||
| P304 | page(s) | 70-75 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | Postępy Dermatologii i Alergologii | Q22965552 |
| P1476 | title | Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome | |
| P478 | volume | 36 |
| Q92997420 | Association of Serum Lipocalin-2 Concentrations with Psoriasis and Psoriatic Arthritis: An Updated Meta-Analysis | cites work | P2860 |
Search more.